Drug-Induced Nephrotoxicity in Inflammatory Bowel Disease
Author(s) -
Konstantinos Oikonomou,
Andreas Kapsoritakis,
Ioannis Stefanidis,
Spyros Potamianos
Publication year - 2011
Publication title -
nephron clinical practice
Language(s) - English
Resource type - Journals
ISSN - 1660-2110
DOI - 10.1159/000326682
Subject(s) - medicine , nephrotoxicity , inflammatory bowel disease , infliximab , drug , disease , renal function , kidney disease , ulcerative colitis , pharmacology , intensive care medicine , kidney
Conservative management of inflammatory bowel disease (IBD) is based on a combination of drugs, including aminosalicylates (ASAs), steroids, antibiotics, immunosuppressives and biologic agents. Although various side effects have been related to treatment regimens, drug-induced nephrotoxicity is rather uncommon. Furthermore, it is often underestimated since renal function deterioration may be attributed to the underlying disease. The nephrotoxicity of ASAs and cyclosporine A seems well established, but recent data have suggested a possible role of biologic agents such as infliximab and adalimubab in renal impairment. The aim of this review is to summarize the nephrotoxic effects of medical treatment as well as to express possible caveats in the administration of novel agents in IBD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom